nAture medicine Mitochondria are dynamic organelles that undergo continual fission and fusion events that are regulated by large GTPases, such as DLP1 for fission and mitofusin 2 (MFN2) for fusion 1 . Unopposed mitochondrial fission or fusion causes human neurological diseases and is increasingly implicated in neurodegenerative diseases, including PD 2-4 . Proteins encoded by previously identified genes associated with familial PD-including α-synuclein (encoded by SNCA), PTEN-induced putative kinase (PINK) 1 (encoded by PINK1), the E3 ubiquitin ligase Parkin (encoded by PARK2), leucine-rich repeat kinase (LRRK) 2 (encoded by LRRK2) and the chaperone DJ-1 (encoded by PARK7)-are localized to mitochondria and are involved in the regulation of mitochondrial dynamics in the same or parallel pathways [5] [6] [7] [8] [9] [10] [11] [12] . Therefore, an altered balance between mitochondrial fission and fusion is probably a common mechanism that leads to impaired mitochondrial quality control and the mitochondrial dysfunction that are critical to PD pathogenesis 13 .
mitochondria in neurons overexpressing VPS35 R524W , whereas neurons overexpressing VPS35 D620N had a more severe mitochondrial fragmentation phenotype. The neurite mitochondrial index, an index for mitochondrial density, was also significantly reduced in neurons overexpressing WT or mutant VPS35 (P < 0.05; Supplementary Fig. 1b) . We measured mitochondrial fission and fusion events by real-time imaging and found that the proportion of fission events (measured as the ratio of fission/(fission + fusion) events) was significantly increased in neurons overexpressing WT or mutated VPS35, as compared to neurons expressing the vector-only control (P < 0.05; Fig. 1d) . Moreover, overexpression of VPS35 WT or VPS35 R524W caused significant neuronal loss, as compared to overexpression of the vector-only control, and this phenotype was more profound in VPS35 D620N -overexpressing cells (P < 0.05; Fig. 1e) .
We further determined whether Vps35 knockdown would induce an effect opposite to that of VPS35 overexpression. We knocked down Vps35 expression by using either of two different microRNA (miR)-based RNA interference (RNAi) constructs specific for Vps35 and found that expression of either miR resulted in mitochondria with significantly increased lengths and aspect ratios and with a decreased proportion of fission events (P < 0.05; Supplementary Fig. 1 ). Of note, we also found that neurons treated with an RNAi construct that specifically suppresses expression of Vps26, which encodes another subunit of the retromer complex 25 , showed a similar increase in the mitochondrial aspect ratio (Supplementary Fig. 2a,b) . Knockdown of Vps26 did not further increase the aspect ratio of mitochondria in cells in which Vps35 had been knocked down. Notably, VPS35 overexpression-induced mitochondrial fragmentation could be abolished by concurrent Vps26 knockdown ( Supplementary Fig. 2c,d ), suggesting that Vps35 and Vps26 are involved in the same pathway.
Mitochondrial dynamics were also examined in M17 human dopaminergic neuroblastoma cells that stably overexpressed the mutated VPS35 genes (Supplementary Fig. 3 ). Consistent with our observations in primary neurons, the mitochondrial aspect ratio decreased in M17 cells overexpressing VPS35 WT or VPS35 R524W . This phenotype was exacerbated in VPS35 D620N -overexpressing M17 cells (Supplementary Fig. 3 ), whereas mitochondria became elongated in M17 cells in which VPS35 expression was knocked down (Supplementary Fig. 4) .
We further analyzed mitochondrial morphology in fibroblasts derived from an individual with PD who had the VPS35 D620N mutation (hereafter referred to as PD D620N fibroblasts) and in normal human fibroblasts (NHFs) from age-matched control subjects ( Fig. 1f-i) . Confocal microscopy analysis revealed an interconnected mitochondrial network in NHFs, which was significantly fragmented in PD D620N fibroblasts (Fig. 1f,g ). Electron microscopy (EM) analysis confirmed that mitochondria in the PD D620N fibroblasts were substantially more fragmented than those in the NHFs (Fig. 1h,i) . (Fig. 1f,g ), supporting the idea that the mitochondrial fragmentation phenotype observed in VPS35 D620N -overexpressing cells is because of increased mitochondrial fission.
VPS35 mutations lead to mitochondrial fragmentation in vivo
To determine the effect of the VPS35 mutations in vivo, we stereotactically injected a lentivirus coexpressing mitoDsRed2 (to fluorescently label mitochondria) and WT or mutated human VPS35 unilaterally into the substantia nigra of 2-to 3-month-old WT FVB or C57BL/6 mice (schematic in Fig. 2a ) and imaged brain sections 3 weeks later. In mice of either background, neurons expressing VPS35 WT or VPS35 R524W had fragmented mitochondria, and the extent of mitochondrial fragmentation was more profound in neurons expressing the VPS35 D620N allele (Fig. 2b,c and Supplementary Fig. 5a,b) . These phenotypes were distinct from the normal tubular-shaped mitochondria observed in the mouse neurons expressing the empty vector and mitoDsRed2. Massive degeneration of tyrosine hydroxylase-positive (TH + ) neurons occurs in the substantia nigra of brains from individuals with PD. There was a trend toward more severe mitochondrial fragmentation in the TH + neurons than in the TH − neurons in mice injected with the VPS35 WT or VPS35 R524W constructs, and this trend reached significance in mice injected with the VPS35 D620N construct (P < 0.05; Fig. 2b,c ). Significant and comparable levels of neuronal loss, both in TH + and TH − neurons, were observed in the mice injected with the VPS35 WT -or VPS35 R524W -expressing construct (Fig. 2d,e and Supplementary Fig. 5c ). The loss of TH + neurons correlated with enhanced mitochondrial fragmentation (data not shown) and was more profound in mice injected with the construct expressing VPS35 D620N . To determine the critical role of VPS35-induced mitochondrial fission in vivo, we treated the mice that had been injected with the VPS35 constructs with mdivi-1. As expected, mdivi-1 treatment blocked VPS35-induced mitochondrial fragmentation in both TH + (Fig. 2f,g ) and TH − neurons (data not shown) in the substantia nigra. Notably, mdivi-1 treatment also prevented VPS35-induced neuronal loss in vivo (Fig. 2h) .
VPS35 mutations cause mitochondrial dysfunction
We assessed the effect of VPS35 mutations on mitochondrial function, as well as on neuronal morphology and viability. As compared to M17 cells treated with the vector-only control, we observed substantial mitochondrial dysfunction in M17 cells that were overexpressing VPS35 WT or VPS35 R524W , and this phenotype was more severe in VPS35 D620N -overexpressing M17 cells, as evidenced by significantly increased production of reactive oxygen species ROS; data not shown), decreased ATP levels and decreased mitochondrial membrane potential (MMP) (P < 0.05, Fig. 3a,b) . Measurement of oxygen consumption rates using the Seahorse XF24 analyzer 27, 28 revealed impaired bioenergetics in these VPS35-expressing M17 cells, as evidenced by a significant reduction in the respiratory control ratio, the spare respiratory capacity and the coupling efficiency ( Supplementary Fig. 6 ). Similar mitochondrial dysfunction (i.e., increased mitochondrial ROS and decreased MMP) to that induced by VPS35 expression was also found in primary cortical neurons (data not shown). Of note, we also observed mitochondrial dysfunction and impaired bioenergetics in PD D620N fibroblasts, as compared to NHFs (Fig. 3c,d and Supplementary Fig. 7 ). Loss of dendritic spines and of synaptic boutons that stain positive for postsynaptic density protein (PSD) 95, a synaptic marker, was apparent in primary neurons expressing WT or mutated VPS35 ( Fig. 3e-g ).
To determine whether excessive fission underlies the VPS35-induced mitochondrial and neuronal deficits, we inhibited mitochondrial fission either by overexpressing a dominant-negative mutant of DLP1 (encoded by DLP1 K38A ) or by treating cells with mdivi-1 to block mitochondrial fragmentation (Fig. 3h-j) . Mdivi-1 treatment did not (e-g) Representative images of dendrites (e) and quantification of dendritic spines (f) and PSD95 + puncta (g) in primary rat cortical neurons (DIV14) cotransfected with mitoDsRed2 and the indicated VPS35 construct, and treated with or without mdivi-1 (vehicle-treated: vector-only control, n = 24; VPS35 WT , n = 23; VPS35 D620N , n = 25; VPS35 R524W , n = 28; mdivi-1-treated: vector-only control, n = 22; VPS35 WT , n = 27; VPS35 D620N , n = 25; VPS35 R524W , n = 25). Scale bar, 1 µm. (h-j) Representative images of primary cortical neurons (boxed segment of axons are enlarged below) (h), and quantification of mitochondrial aspect ratio in the axon (i) and the percentage of neurons with fragmented mitochondria (j) in primary cortical neurons expressing mitoDsRed2, dominant-negative DLP1 (encoded by DLP1 K38A ) and the indicated VPS35 constructs (vector-only control, n = 25; VPS35 WT , n = 23; VPS35 D620N , n = 26; VPS35 R524W , n = 28; vector + DLP1 K38A , n = 30; VPS35 WT + DLP1 K38A , n = 21; VPS35 D620N + DLP1 K38A , n = 22; VPS35 R524W + DLP1 K38A , n = 29; vector + mdivi-1, n = 31; VPS35 D620N + mdivi-1, n = 25). Throughout, n represents the number of neurons per group. Data are means ± s.e.m. from three independent experiments. *P < 0.05; n.s., not significant; one-way ANOVA with Tukey's multiple-comparison test.
npg affect DLP1 expression and phosphorylation (Supplementary Fig. 8 ).
The inhibition of mitochondrial fragmentation rescued the VPS35-induced mitochondrial dysfunction both in neuronal cells overexpressing VPS35 (Fig. 3a,b ) and in PD D620N fibroblasts (Fig. 3c,d and Supplementary Fig. 7 ). Neuronal deficits (i.e., the loss of spines and PSD95 immunoreactivity) ( Fig. 3e-g ) were also rescued.
VPS35 regulates mitochondrial DLP1 complex turnover
Western blot analysis demonstrated that total DLP1 levels were slightly increased in VPS35-overexpressing M17 cells and decreased in M17 cells in which VPS35 expression had been knocked down (Supplementary Fig. 9 ). Real-time PCR confirmed a substantial increase in DLP1 mRNA levels in VPS35-overexpressing M17 cells (data not shown). We did not observe any significant changes for other fission and fusion proteins.
As compared with vector-only control lines, levels of mitochondrial DLP1 were significantly increased in VPS35 WT -or VPS35 R524W -overexpressing M17 cells, and this became more profound in VPS35 D620N -overexpressing M17 cells but significantly reduced in M17 cells in which VPS35 expression had been knocked down (P < 0.05, Fig. 4a,b) , suggesting that VPS35 facilitates mitochondrial translocation of DLP1 and that this is enhanced by PD-associated mutations. To corroborate this finding, we imaged mitochondrial DLP1 in M17 cells that were fixed and immunostained for DLP1. Unexpectedly, the density and average size of the mitochondrial DLP1 puncta were significantly decreased in VPS35-overexpressing M17 cells but significantly increased in M17 cells knocked down for VPS35 (P < 0.05, Fig. 4c,d) . Because mitochondrial DLP1 assembles into large complexes and as the DLP1 puncta on mitochondria probably represent the mitochondrial DLP1 complex 29 , this finding suggests that VPS35 may regulate To test this possibility, we expressed GFP-tagged DLP1 (GFP-DLP1) in M17 cells and used the 'fluorescent recovery after photobleaching' (FRAP) technique to measure the lifetime of mitochondrial GFP-DLP1 puncta by real-time imaging. VPS35 overexpression significantly shortened, whereas VPS35 knockdown significantly extended, the lifetime of the puncta (P < 0.05; Fig. 4e ). This is probably not because of the difference in diffusion-limited kinetics, as the fluorescence recovery of mitochondrial GFP-DLP1 was not dependent on the size of the bleached area and because all of the stable cell lines had similar kinetics of GFP-DLP1 recovery in cytosolic areas that were devoid of mitochondria (data not shown). To determine the levels of mitochondrial DLP1 complexes, we prepared mitochondrial fractions from cells that were exposed to the reversible crosslinking agent dithiobismaleimidoethane (DTME), precipitated large mitochondrial protein complexes from these fractions by ultracentrifugation (which we refer to as 270K pellets) and analyzed DLP1 levels using SDS-PAGE and western blotting. DLP1 levels were significantly decreased in the 270K pellets from VPS35 WToverexpressing M17 cells but significantly increased in pellets from M17 cells after knocking down VPS35 expression (Fig. 4f) . Notably, DLP1 levels were also significantly decreased in 270K pellets from PD D620N fibroblasts, as compared to DLP1 levels in 270K pellets from NHFs (P < 0.05; Fig. 4g ). The use of an irreversible cross-linking agent (such as disuccinimidyl suberate (DSS)) allows direct detection of oligomeric DLP1 complexes and monomeric DLP1 (refs. 29-32) . Indeed, western blot analyses of mitochondrial fractions from DSS-treated cells demonstrated that levels of oligomeric DLP1 complexes were significantly decreased in VPS35-overexpressing cells but significantly increased in M17 cells after knocking down VPS35 expression (Fig. 4h,i) . In contrast, levels of monomeric mitochondrial DLP1 was significantly increased in cells in which VPS35 was overexpressed but decreased in cells in which VPS35 expression was knocked down (Fig. 4h,i) . Knockdown of VPS26 expression increased the number of mitochondrial DLP1 puncta and the levels of oligomeric DLP1complexes, but did not cause any further increases in these phenotypes in cells that had also been knocked down for VPS35 expression (Supplementary Fig. 10a,b) . Of note, the effect of VPS35 overexpression on mitochondrial DLP1 complexes could be reversed by VPS26 knockdown (Supplementary Fig. 10c ).
VPS35-DLP1 interaction is key to the turnover of mitochondrial DLP1
To determine the biochemical basis of the regulatory role of VPS35 in mitochondrial dynamics, we investigated whether VPS35 interacts with DLP1. We imaged M17 cells that were transfected with mitoDsRed2 and immunostained with antibodies specific for DLP1 or VPS35. The 3D-reconstructed images demonstrated the colocalization of DLP1 puncta and VPS35 on mitochondria (Fig. 5a) . We also found a strong interaction between VPS35 and DLP1 using yeast twohybrid analysis (Fig. 5b) . In M17 cells, endogenous VPS35 could be co-immunoprecipitated by the DLP1-specific antibody and vice versa (Fig. 5c,d) . We confirmed the presence of endogenous VPS35 in purified mitochondrial fractions (Fig. 5e) 21 . Indeed, endogenous DLP1 in mitochondrial fractions co-immunoprecipitated with VPS35 (Fig. 5f) . By using purified mitochondrial fractions and a VPS35-specific antibody, we found that significantly more DLP1 was pulled down from M17 cells expressing VPS35 D620N than from cells expressing VPS35 WT , suggesting that there was an enhanced interaction between DLP1 and the VPS35 D620N mutant (Fig. 5f) . Indeed, increased VPS35-DLP1 interaction was confirmed in the PD D620N fibroblasts as compared npg to that in NHFs (Fig. 5g) . Increased VPS35-DLP1 interaction was also found in hydrogen peroxide-treated or paraquat-treated M17 cells, which was inhibited by concurrent treatment with the antioxidant N-acetylcysteine (Supplementary Fig. 11 ), suggesting that oxidative modification may enhance the VPS35-DLP1 interaction. Increased oxidative stress is a prominent feature of PD 2 , and increased VPS35-DLP1 interactions were found in postmortem brain samples of individuals with sporadic PD (Fig. 5h) .
The VPS35 D620N mutant showed an enhanced interaction with DLP1 (Fig. 5f,g ). Not unexpectedly, mutations introduced at residue D620 differentially impacted the VPS35-DLP1 interaction-VPS35 D620E and VPS35 D620I decreased the interaction, VPS35 D620A and VPS35 D620R did not affect it, and VPS35 D620Y increased VPS35's interaction with DLP1 (Fig. 5i) . These mutants also had differential effects on the accumulation of mitochondrial DLP1 complexes in M17 cells after knockdown of endogenous VPS35 (Fig. 5j) . Overexpression of VPS35 WT , VPS35 D620A or VPS35 D620R significantly reduced the levels of mitochondrial DLP1 complexes in the 270K pellets, whereas overexpression of VPS35 D620N or VPS35 D620Y caused even further reductions (P < 0.05). Overexpression of VPS35 D620E or VPS35 D620I did not have any effect on the levels of mitochondrial DLP1 complexes (Fig. 5j) . Consistently, these mutants also had differential effects on the elongated mitochondrial morphology observed in M17 cells after VPS35 knockdown (Supplementary Fig. 12a,b) . Overexpression of VPS35 WT , VPS35 D620A or VPS35 D620R enhanced fission to restore the normal filamentous mitochondrial morphology. Overexpression of VPS35 D620N or VPS35 D620Y resulted in even shorter mitochondria, whereas expression of VPS35 D620E or VPS35 D620I failed to rescue the elongated mitochondrial morphology (Supplementary Fig. 12a,b) , suggesting that fission is deficient in cells expressing the latter two mutants. In a control experiment, we found that knocking down VPS35 reduced retromer activity, as evidenced by reduced recycling of the fatty-acid translocator (FAT; also referred to as CD36)(ref. 33) , and that expression of each VPS35 mutant (under these conditions) restored FAT (CD36) recycling to a level comparable to that observed with endogenous VPS35 (Supplementary Fig. 12c) , demonstrating that retromer function was not impaired in these mutants. Collectively, these data strongly support that the VPS35-DLP1 interaction is essential for mitochondrial DLP1 complex turnover, which is required for efficient mitochondrial fission.
MDV mediates VPS35-dependent mitochondrial DLP1 turnover
The retromer is involved in MDV formation, and MDVs can transport mitochondrial proteins to lysosomes 22, 34 . We investigated whether DLP1 is localized to MDVs. MDVs contain mitochondrial outermembrane proteins, such as TOM20, but not mitochondrial matrix proteins such as cytochrome c oxidase (COX) IV and mitoDsRed2 (ref. 21) . To reconstitute MDVs in vitro, we used a cell-free budding assay 35 . Western blot analysis demonstrated the presence of trypsinresistant proteins incorporated within MDVs, such as TOM20, and the absence of COX IV in the post-mitochondria supernatant after treatment with trypsin (Fig. 6a) , confirming the successful reconstitution of MDVs in vitro. As expected, the TOM20 signal in reconstituted MDVs was enhanced by addition of a cytosolic fraction to the in vitro reaction mixture and abolished in the presence of N-ethymaleimide (NEM), a cell-free membrane transport inhibitor (Fig. 6a) . DLP1 behaved similarly to TOM20 (Fig. 6a) , suggesting that DLP1 is a cargo of MDVs. The enrichment of trypsin-resistant DLP1 incorporated within MDVs in the post-mitochondrial supernatant after treatment with trypsin was time dependent (i.e., the longer the treatment, the more the accumulation of DLP1). Moreover, DLP1 enrichment was significantly stimulated by the presence of cytosolic fractions from VPS35-overexpressing versus vector-only control M17 cells (P < 0.05; Fig. 6b,c) and significantly reduced in the presence of cytosolic fractions from M17 cells after knocking down VPS35 expression (P < 0.05; Fig. 6b,c) .
By using electron microscopy (EM) on purified mitochondria, we readily observed 60-to 100-nm, single-or double-membraned vesicular structures attached to the mitochondrion, consistent with previous descriptions of MDVs 36 (Fig. 6d) . Immuno-EM with a highly specific antibody to DLP1 (Supplementary Fig. 13 ) revealed the presence of DLP1 + immunogold particles in these MDVs (Fig. 6e) . This was corroborated by confocal imaging analyses in which DLP1 puncta colocalized with TOM20 + mitoDsRed2 − MDVs in M17 cells (Fig. 6f) . Of note, the colocalization of DLP1 with MDVs was significantly increased in M17 cells after VPS35 overexpression but decreased in M17 cells after VPS35 knockdown (Fig. 6g,h) , suggesting that VPS35 mediates the MDV-dependent transport of DLP1.
3D-reconstructed images showed the presence of DLP1 punctaassociated MDVs in lysosomes (Fig. 6i) , which was reduced by VPS35 knockdown but increased by overexpression of VPS35 WT or VPS35 D620N (Fig. 6j) . The presence of DLP1 puncta-associated MDVs in lysosomes was inversely correlated with the density of the mitochondrial DLP1 puncta (data not shown). Indeed, inhibition of lysosomal degradation by treating cells with bafilomycin A1 led to increased accumulation of DLP1 puncta-associated MDVs in lysosomes (Fig. 6j) , thus confirming degradation to be the final fate of the DLP1 complexes that are trafficked to lysosomes via MDVs. We found no differences in peroxisomal DLP1 levels in cells that overexpressed VPS35 or those in which VPS35 was knocked down ( Supplementary  Fig. 14) , suggesting that VPS35-dependent DLP1-containing MDVs do not traffic to peroxisomes.
DISCUSSION
We found that the PD-associated VPS35 D620N mutation causes extensive mitochondrial fragmentation and functional deficits, and leads to neuronal loss both in vitro and in the substantia nigra of mouse brain in vivo. This could be rescued by inhibiting excessive mitochondrial fission, suggesting that the VPS35 mutation probably causes neurodegeneration through damaging effects on mitochondrial dynamics and function. These effects of the PD-associated VPS35 mutation are probably specific effects of the mutation and independent of potential overexpression artifacts because: (i) in the VPS35 D620N -expressing fibroblasts from an individual with PD, mitochondria were fragmented and functionally impaired; (ii) elongated mitochondria that were observed in M17 cells after VPS35 knockdown could be restored to their normal filamentous shape by re-expression of VPS35 WT ; however, the elongated mitochondria were fragmented by expression of VPS35 D620N at levels similar to those of VPS35 WT ; and (iii) a VPS35-DLP1 interaction was found in normal M17 cells and in NHFs, and this interaction was found to be enhanced in fibroblasts from an individual with PD who has the VPS35 D620N allele.
Mechanistically, we describe a novel concept for the biology of mitochondrial fission by revealing the involvement of VPS35 and the retromer complex in the recycling of mitochondrial DLP1 complexes and in the regulation of mitochondrial fission (Supplementary Fig. 15 ). DLP1 complexes present on the mitochondrial outer membrane remain with the daughter mitochondrion after fission 37 and probably become inhibitory for subsequent fission events owing to the occupancy of fission sites or to the sequestration of DLP1 recruiting npg factors [29] [30] [31] [32] 38, 39 . Here we demonstrated that the retromer, through a VPS35-DLP1 interaction, mediates the removal of these DLP1 complexes from mitochondria and transports them, via the formation and trafficking of MDVs, to lysosomes for degradation-a process that effectively alleviates the inhibitory effects of the mitochondrial DLP1 complexes and that is probably required for efficient mitochondrial fission. The PD-associated VPS35 mutant resulted in an increased VPS35-DLP1 interaction and enhanced the retromer-dependent turnover of mitochondrial DLP1 complexes via MDV-mediated trafficking. Thus, it tipped the balance of mitochondrial dynamics toward excessive fission, which has been found to lead to mitochondrial dysfunction and neuronal loss 40 . We further demonstrated that increased oxidative stress enhances the VPS35-DLP1 interaction, a mechanism that may underlie the increased VPS35-DLP1 interaction observed in the brains of individuals with sporadic PD. These data support a more general role for the dysregulation of VPS35-mediated mitochondrial DLP1 complex turnover in causing abnormal mitochondrial dynamics and mitochondrial dysfunction that are critical to PD pathogenesis.
Various PD-associated proteins are involved in the regulation of mitochondrial dynamics. PINK1 and Parkin regulate the ubiquitination and degradation of MFN2 and DLP1, whereas LRRK2 increases DLP1 recruitment to mitochondria 5, 8, 9 . Here we revealed a novel cellular mechanism for the regulation of mitochondrial fission at the level of turnover of the mitochondrial DLP1 complex; this was enhanced by the PD-associated VPS35 D620N mutant. Nevertheless, our study does not exclude the possibility that other cellular functions may be negatively impacted by VPS35 mutations. Recent studies have revealed that the VPS35 D620N mutation also leads to a defect in its binding to the Wiskott-Aldrich syndrome protein and scar homolog (WASH) complex and perturbation in endosome-to-Golgi transport and autophagosome biogenesis [41] [42] [43] .
METHODS
Methods and any associated references are available in the online version of the paper. 
